

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)

PCT (10) International Publication Number
WO 2005/037083 A2

- (51) International Patent Classification⁷: A61B
- (21) International Application Number:
PCT/US2004/034573
- (22) International Filing Date: 18 October 2004 (18.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/511,832 16 October 2003 (16.10.2003) US
- (71) Applicant (for AM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG only): BAYER HEALTH-CARE [US/US]; Diagnostic Business Group, 511 Benedict Avenue, Tarrytown, NY 10591-5097 (US).
- (71) Applicant (for all designated States except US): INSTITUTE OF VIROLOGY [SK/SK]; Slovak Academy of Sciences, Dúbravská Cesta 9, 842 46 Bratislava (SK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EBERT, Matthias [DE/DE]; Lentkestrasse 57, 39116 Magdeburg (DE).

ROCKEN, Christoph [DE/DE]; Brönnertstrasse 24, 39112 Magdeburg (DE). PASTOREKOVÁ, Silvia [SK/SK]; Novoveska 18, 841 07 Bratislava (SK). ZAVADA, Jan [CZ/CZ]; Na pekne vyhlidce 1, 162 00 Prague (CZ). PASTOREK, Jaromir [SK/SK]; Novoveska 18, 841 07 Bratislava (SK).


(74) Agent: LAUDER, Leona, L.; Suite 450, 465 California Street, San Francisco, CA 94104-1840 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: MN/CA IX AND CANCER PROGNOSIS



(57) Abstract: Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.